Evidence map›Paper›PMID 37397398›Full record

ArticleFrontiers in oncology2023

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin.

Ryutaro Onaga, Tomohiro Enokida, Kazue Ito, Yuri Ueda, Susumu Okano, Takao Fujisawa, Akihisa Wada, Masanobu Sato, Hideki Tanaka, Naohiro Takeshita and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Contemporary Management of Malignancies of the Parotid Gland: A State-of-the-Art Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ryutaro OnagaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kazue ItoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yuri UedaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Susumu OkanoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takao FujisawaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Akihisa WadaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Masanobu SatoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hideki TanakaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Naohiro TakeshitaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Nobukazu TanakaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yuta HoshiDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite advances in precision medicine, most patients with recurrent or metastatic salivary gland carcinoma still need conventional chemotherapies, such as the combination of taxane and platinum. However, evidence for these standardized regimens is limited. Methods: We retrospectively reviewed patients with salivary gland carcinoma treated with a taxane and platinum, which contained docetaxel at a dose of 60 mg/m2 plus cisplatin at a dose of 70 mg/m2 on day 1, or paclitaxel at a dose of 100 mg/m2 plus carboplatin at a dose of area under the plasma concentration-time curve = 2.5 on days 1 and 8 (both on 21-day cycles), between January 2000 and September 2021. Result: Forty patients with ten adenoid cystic carcinomas and thirty other pathologies were identified. Of these, 29 patients were treated with docetaxel plus cisplatin and 11 with paclitaxel plus carboplatin. For the total population, the objective response rate (ORR) and median progression-free survival (mPFS) were 37.5% and 5.4 months (95% confidence interval: 3.6-7.4 months), respectively. On subgroup analysis, docetaxel plus cisplatin provided favorable efficacy compared with paclitaxel plus carboplatin (ORR: 46.5% Conclusion: The combination of taxane and platinum is generally effective and well-tolerated for recurrent or metastatic salivary gland carcinoma. In contrast, paclitaxel plus carboplatin appears unfavorable in terms of efficacy in certain patients, such as those with adenoid cystic carcinoma.

Indexed as

adenoid cystic carcinomacisplatincytotoxic chemotherapydocetaxelsalivary gland carcinoma

Identifiers

PMID37397398
PMCPMC10311248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.